Elevated serum levels of S100 and survival in metastatic malignant melanoma.

Current reports suggest serum S100 as a prognostic marker for disease progression in advanced malignant melanoma. In this study, we assessed serum levels of S100 and multiple clinical factors in relation to overall survival in 99 patients with metastatic malignant melanoma seen at our institution be...

Descripción completa

Detalles Bibliográficos
Autores principales: Buer, J., Probst, M., Franzke, A., Duensing, S., Haindl, J., Volkenandt, M., Wittke, F., Hoffmann, R., Ganser, A., Atzpodien, J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228235/
https://www.ncbi.nlm.nih.gov/pubmed/9155061
_version_ 1782149862986350592
author Buer, J.
Probst, M.
Franzke, A.
Duensing, S.
Haindl, J.
Volkenandt, M.
Wittke, F.
Hoffmann, R.
Ganser, A.
Atzpodien, J.
author_facet Buer, J.
Probst, M.
Franzke, A.
Duensing, S.
Haindl, J.
Volkenandt, M.
Wittke, F.
Hoffmann, R.
Ganser, A.
Atzpodien, J.
author_sort Buer, J.
collection PubMed
description Current reports suggest serum S100 as a prognostic marker for disease progression in advanced malignant melanoma. In this study, we assessed serum levels of S100 and multiple clinical factors in relation to overall survival in 99 patients with metastatic malignant melanoma seen at our institution between May 1990 and April 1996. For statistical analysis, we used both univariate and multivariate Cox proportional-hazards models. Elevated serum levels of S100 correlated with poor outcome in metastatic malignant melanoma (P < 0.0001), univariate analysis). Upon multivariate analysis, however, S100 added no information to known clinical prognostic parameters.
format Text
id pubmed-2228235
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22282352009-09-10 Elevated serum levels of S100 and survival in metastatic malignant melanoma. Buer, J. Probst, M. Franzke, A. Duensing, S. Haindl, J. Volkenandt, M. Wittke, F. Hoffmann, R. Ganser, A. Atzpodien, J. Br J Cancer Research Article Current reports suggest serum S100 as a prognostic marker for disease progression in advanced malignant melanoma. In this study, we assessed serum levels of S100 and multiple clinical factors in relation to overall survival in 99 patients with metastatic malignant melanoma seen at our institution between May 1990 and April 1996. For statistical analysis, we used both univariate and multivariate Cox proportional-hazards models. Elevated serum levels of S100 correlated with poor outcome in metastatic malignant melanoma (P < 0.0001), univariate analysis). Upon multivariate analysis, however, S100 added no information to known clinical prognostic parameters. Nature Publishing Group 1997 /pmc/articles/PMC2228235/ /pubmed/9155061 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Buer, J.
Probst, M.
Franzke, A.
Duensing, S.
Haindl, J.
Volkenandt, M.
Wittke, F.
Hoffmann, R.
Ganser, A.
Atzpodien, J.
Elevated serum levels of S100 and survival in metastatic malignant melanoma.
title Elevated serum levels of S100 and survival in metastatic malignant melanoma.
title_full Elevated serum levels of S100 and survival in metastatic malignant melanoma.
title_fullStr Elevated serum levels of S100 and survival in metastatic malignant melanoma.
title_full_unstemmed Elevated serum levels of S100 and survival in metastatic malignant melanoma.
title_short Elevated serum levels of S100 and survival in metastatic malignant melanoma.
title_sort elevated serum levels of s100 and survival in metastatic malignant melanoma.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228235/
https://www.ncbi.nlm.nih.gov/pubmed/9155061
work_keys_str_mv AT buerj elevatedserumlevelsofs100andsurvivalinmetastaticmalignantmelanoma
AT probstm elevatedserumlevelsofs100andsurvivalinmetastaticmalignantmelanoma
AT franzkea elevatedserumlevelsofs100andsurvivalinmetastaticmalignantmelanoma
AT duensings elevatedserumlevelsofs100andsurvivalinmetastaticmalignantmelanoma
AT haindlj elevatedserumlevelsofs100andsurvivalinmetastaticmalignantmelanoma
AT volkenandtm elevatedserumlevelsofs100andsurvivalinmetastaticmalignantmelanoma
AT wittkef elevatedserumlevelsofs100andsurvivalinmetastaticmalignantmelanoma
AT hoffmannr elevatedserumlevelsofs100andsurvivalinmetastaticmalignantmelanoma
AT gansera elevatedserumlevelsofs100andsurvivalinmetastaticmalignantmelanoma
AT atzpodienj elevatedserumlevelsofs100andsurvivalinmetastaticmalignantmelanoma

Ejemplares similares